"We are advancing cures and meaningful treatments at record speed at the FDA," Makary said on “Katie Pavlich Tonight.” ...
A massive overhaul of staffing and review processes have left the agency appearing heavily driven by the Trump administration ...
FDA commissioner Marty Makary said it would be “magical” for consumers to see prescription drugs on pharmacy shelves instead ...
Dr. Mark McClellan, Duke University health policy director and former FDA commissioner, joins 'Squawk Box' to discuss the Trump administration's plan to hold Medicare Advantage rate increases near ...
15don MSN
Legal questions swirl around FDA's new expedited drug program, including who should sign off
The Food and Drug Administration commissioner's effort to drastically shorten the review of drugs favored by President Donald Trump's administration is causing alarm across the agency, stoking worries ...
Echoing President Donald Trump’s call to accelerate medical innovation, Food and Drug Administration (FDA) Commissioner Marty Makary announced that the agency will no longer block companies from ...
Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on drugs cleared under a new plan to slash FDA drug review times.
On June 17, 2025, FDA Commissioner Marty Makary launched a new priority review pilot program intended to accelerate FDA review for drug and biologic companies supporting U.S. national interests.
CNN — Dr. Scott Gottlieb, commissioner of the US Food and Drug Administration, is leaving the agency next month, according to an administration official familiar with the situation. This official said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results